Preferences help
enabled [disable] Abstract
Number of results
2018 | 8 | 3 | 65-69
Article title

Cardio-oncology in Ukraine: experience at Strazhesko Institute of Cardiology

Title variants
Languages of publication
Anticancer therapies have extended the lives of patients with cancer, but for some, this benefit is tempered by cardiovascular complications. Their number is increasing as a result of an improvement in the early diagnosis of cardiotoxicity caused by chemo- and radiotherapy. Therefore prevention, detection, monitoring, and treatment of cancer patients at risk of cardiotoxicity with or without concomitant CV diseases are very important. Cardio-oncology is a new direction in Ukraine for improving clinical outcomes of cancer patients. This review aims to provide an overview of the rationale for setting up a Cardio-Oncology Unit and reflects our own experience establishing this service.
Physical description
  • Cardio-Oncology Unit, National Scientific Center M.D. Strazhesko Institute of Cardiology, Kyiv, Ukraine
  • Cardio-Oncology Unit, National Scientific Center M.D. Strazhesko Institute of Cardiology, Kyiv, Ukraine
  • Ukrainian National Cancer Institute, Kyiv, Ukraine
  • Ukrainian National Cancer Institute, Kyiv, Ukraine
  • 1. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55(3): 213-220.
  • 2. Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr Cardiol Rep 2016; 18: 51.
  • 3. Tromp J, Steggink LC, Van Veldhuisen DJ et al. Cardio-oncology: progress in diagnosis and treatment of cardiac dysfunction. Clin Pharmacol Ther 2017; 101: 481-490.
  • 4. Kim KW, Shinagare AB, Krajewski KM et al. Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management. Korean J Radiol 2015; 16(2): 304-313.
  • 5. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 2015; 12(9): 547-558.
  • 6. Reports of State Expert Centre of the Ministry of Health of Ukraine [online:].
  • 7. Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al. 2016 ESC Position Paper cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016; 37: 2768-2801.
  • 8. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27(9): 911-939.
  • 9. Herrmann J, Lerman A. An update on cardio-oncology. Trends Cardiovasc Med 2014; 24(7): 285-295.
  • 10. Lancellotti P, Suter TM, López-Fernández T et al. Cardio-Oncology Services: rationale, organization and implementation. A report from the ESC Cardio-Oncology council. Eur Heart J 2018; 6. DOI: 10.1093/eurheartj/ehy453 [Epub ahead of print].
  • 11. Läubli H, Balmelli C, Bossard M et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015; 3: 11.
  • 12. Koelzer VH, Rothschild SI, Zihler D et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 2016; 4: 13.
  • 13. Barac A, Murtagh G, Carver JR et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol 2015; 65: 2739-2746.
  • 14. der Meer P, Gietema JA, Suter TM et al. Cardiotoxicity of breast cancer treatment: no easy solution for an important long-term problem. Eur Heart J 2016; 37: 1681-1683.
  • 15. Nhola LF, Villarraga HR. Rationale for Cardio-Oncology Units. Rev Esp Cardiol 2017; 70: 583-589.
  • 16. Parent S, Pituskin E, Paterson DI. The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease. Can J Cardiol 2016; 32: 847-851.
  • 17. Borras JM, Albreht T, Audisio R et al. European Policy statement on multidisciplinary cancer care. European Partnership Action Against Cancer: consensus group. J Cancer 2014; 50: 475-480.
  • 18. Cubbon RM, Lyon AR. Cardio-oncology: concepts and practice. Indian Heart J 2016; 68(Suppl 1): S770-S785.
  • 19. Lancellotti P, Anker SD, Donal E et al. EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry) – EURObservational Research Program of the European Society of Cardiology. Eur Heart J Cardiovasc Imaging 2015; 16: 466-470.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.